Relugolix Drug Asset Due Diligence Report 2026

This Relugolix Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.

Decision date: 15 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.

Approved

Highest phase

105

Registered trials

Result records

Matched deals

Executive recommendation: GO

Decision memo

Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.

The central underwriting question is whether Relugolix can convert its Small molecule drug profile and GnRHR biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.

1. Asset identity and development status

Asset	Relugolix (query alias: relugolix)
Modality / target	Small molecule drug; GnRHR; GnRHR antagonists
Highest global status	Approved
Originator	Takeda Pharmaceutical Co., Ltd.
Active developers	Sumitomo Pharma America, Inc., Sumitomo Pharma Switzerland GmbH, Accord Healthcare SL

The MCP disease footprint includes Advanced Prostate Carcinoma, Castration-sensitive prostate cancer, Endometriosis. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.

2. Clinical program: design and endpoint audit

Registry	Phase	Status	Enrollment	Lead primary endpoint
CTR20262412	Phase 3	进行中（尚未招募）	110	Not disclosed
CTR20262234	Phase 3	进行中（尚未招募）	110	Not disclosed
CTR20262057	Not Applicable	进行中（尚未招募）	36	Not disclosed

The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.

Reproduce the asset-to-trial workflow with PatSnap MCP

3. Clinical readouts: what is known

Relugolix Versus Leuprolide in Patients With Prostate Cancer: A Randomized, Open-Label Study to Assess Major Adverse Cardiovascular Events (REPLACE-CV)

Phase 3; n=387; evaluation: not stated. Reported fields: -; Number of Patients With Adverse Events and Serious Adverse Events = 94 Participants ; -

Testosterone suppression, safety, and adherence with relugolix in patients with metastatic prostate cancer: 6-month subgroup analysis of the OPTYX study.

Not Applicable; n=255; evaluation: Positive. Reported fields: Adherence(never forgetting to take relugolix even once) = 83.0 % ; Adherence(never forgetting to take relugolix even once) = 80.0 %

OPTIMAS: A phase II randomized, decentralized, de-escalation trial in patients (pts) with metastatic hormone-sensitive prostate cancer (mHSPC) achieving optimal PSA response.

Phase 2; n=160; evaluation: Positive. Reported fields: BFI-3 = 2.04 point

These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.

4. Market and competitive position

Relugolix addresses Advanced Prostate Carcinoma, Castration-sensitive prostate cancer, Endometriosis. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Small molecule drug—must demonstrate a benefit large enough to offset class-specific safety and operational costs.

The strongest market-validation signal in this screen is partner behavior: 7 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.

5. Transaction precedent and economics

Date	Transaction	Phase at deal	Disclosed economics
2025-06-05	Knight Therapeutics and Sumitomo Pharma enter into Exclusive Licensing Agreements to commercialize Sumitomo’s Canadian Portfolio	Approved	US$18.5M upfront; US$16.5M milestones
2022-10-03	Sumitovant Biopharma Completes Acquisition of Myovant Sciences	Approved	Financial terms not disclosed
2022-05-05	Accord partners with Myovant Sciences to develop and commercialize relugolix for advanced hormone-sensitive prostate cancer in the European Economic Area, United Kingdom, Switzerland, and Turkey.	Approved	Financial terms not disclosed

Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.

6. IP and freedom-to-operate screen

The milestone feed surfaced a patent-application signal described as “Long-acting formulation composition of relugolix”.

The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.

7. Principal risks and diligence gates

Therapeutic index across KRAS/BRAF mutation subgroups
On-target toxicity and adaptive MAPK resistance
Lack of matched efficacy results in the current MCP result set

Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.

8. Final go/no-go memorandum

GO